Puma Biotechnology Reports $3.8 Million Net Loss in Q1 2026, Revenue Declines

Puma Biotechnology, Inc. reported a net loss of approximately $3.8 million for the first quarter of 2026, a significant decline from a net income of $3.0 million in the same period of 2025. Total revenue for the quarter was approximately $44.8 million, down from $46.0 million year-over-year. The decrease was primarily attributed to a reduction in product revenue, which fell to $42.0 million from $43.1 million, largely due to increased deductions for variable considerations such as government chargebacks. Royalty revenue remained stable at approximately $2.9 million for both periods.

Operating expenses increased to $48.6 million in the first quarter of 2026, compared to $42.0 million in the prior year. This rise was driven by a notable increase in research and development expenses, which surged to $19.8 million from $13.9 million, reflecting heightened activity related to the development of alisertib, a drug the company in-licensed from Takeda Pharmaceutical Company in September 2022. Selling, general, and administrative expenses also rose to $18.4 million, up from $17.6 million, primarily due to increased payroll and professional fees.

Puma's cash and cash equivalents stood at $36.2 million as of March 31, 2026, an increase from $29.6 million at the end of 2025. The company also held marketable securities worth $65.4 million, down slightly from $67.9 million. Cash provided by operating activities was approximately $15.4 million, a significant increase from $3.6 million in the previous year, driven by a decrease in accounts receivable. The company’s current liabilities decreased to $59.7 million from $81.3 million, primarily due to a reduction in the current portion of long-term debt.

Looking ahead, Puma Biotechnology remains focused on the commercialization of NERLYNX and the development of alisertib. The company has received regulatory approvals for NERLYNX in over 60 countries outside the United States and plans to continue expanding its market presence. However, the company acknowledges the need for additional funding to support ongoing operations and product development, particularly as it navigates the complexities of the biopharmaceutical market. The company believes its existing cash and marketable securities will be sufficient to meet its operational needs for at least the next year, although it remains dependent on successful commercialization efforts and potential future financing.